Elevated Galectin-3 Level Predicts Pulmonary Artery Hypertension

Alexander E. Berezin
Internal Medicine Department, State Medical University of Zaporozhye
26 Mayakovsky av., Zaporozhye, UA-69035, Ukraine

Abstract
Pulmonary arterial hypertension (PAH) is a heterogenic group of devastating disorders that characterizes higher rates of mortality and morbidity worldwide. Recent clinical studies have shown that clinical features, hemodynamic parameters, echocardiography pattern, multi-spiral computer tomography findings, exercise capacity, and anti-nuclear antibody profiles could be used as predictors of clinical severity and outcomes in PAH patients. However, the reliability, sensitivity, specificity and predictive value are derived from PAH patients with different comorbidities and specific complications associated with CTD, congenital heart disease and respiratory disease might be unacceptable. The aim of the mini review: to summarize the knowledge regarding predictive value of galectin-3 as a biomarker in PAH individuals. The mini review is argued the perspective to utilize single sample and serial measurements of Gal-3 as a regulatory peptide contributed in PAH pathogenesis aimed to improve prediction of PAH development and progression.

Keywords: pulmonary artery hypertension; galectin-3; biomarkers; prognostication

Introduction
Pulmonary arterial hypertension (PAH) is a heterogenic group of distinct disorders that includes idiopathic PAH (IPAH), familial PAH and PAH associated with other conditions (APAH) such as connective tissue disease (CTD-APA), respiratory disease, congenital or acquired left-heart inflow/outflow obstructive lesions or congenital cardiomyopathies etc. [1, 2]. PAH is characterized by pulmo-
nary capillary endothelial metabolic dysfunction directly related to microvascular inflammation that leads to increased pulmonary arterial pressure and pulmonary vascular resistance [3-5]. Despite histological findings that are suitable for the pulmonary vascular lesions in PAH complicating CTD are similar to those observed in IPAH, familial PAH and APAH, morbidity and mortality rates between these patient cohorts sufficiently distinguish. Compared with IPAH patients and familial PAH individuals, patients with PAH associated with CTD have an older age of onset and exhibited worse prognosis in survival [6] Survival of patients with respiratory disease-related or congenital heart disease-related PAH in the modern treatment era is better than CTD-APAH [6, 7]. Although clinical features, hemodynamic parameters, echocardiography pattern, multi-spiral computer tomography findings, exercise capacity, and anti-nuclear antibody profiles were found as powerful factors predicted a development of PAH due to several diseases [8], the reliability, sensitivity, specificity and predictive value are derived from PAH patients with different comorbidities and specific complications associated with CTD, congenital heart disease and respiratory disease might be unacceptable [9]. In this context, taken into consideration pathophysiological heterogeneity of PAH to risk stratification based on biological markers (N-terminal pro-brain natriuretic peptide, red cell distribution width, soluble endoglin, growth differentiation factor-15, interleukin-6, soluble vascular endothelial growth factor receptor-1, C-reactive protein, pentraxin 3) reflected several faces of nature evolution of the disease might be useful and appears to be attractive [10-13]. Recent pre-clinical and clinical studies have been indicated an important role for Galectin-3 (Gal-3) signaling mechanism in the pathophysiology of IPAH and PAH-CTD [14-16]. Moreover, it has been suggested that Gal-3 may serve as biomarkers for functional status and progression of disease [15]. The aim of the mini review: to summarize the knowledge regarding predictive value of galectin-3 as a biomarker in PAH individuals.

The biological role and function of Gal-3

Gal-3 is an adhesion-modulated and growth-regulatory β-galactoside-binding lectin that secreted by activated mononuclears / macrophages and contributed to various pathophysiological processes affected cardiac / vascular remodeling, cardiac fibrosis, and inflammation [17]. As a multifactorial regulator of cell function Gal-3 is involved in cell proliferation / differentiation, angiogenesis, neovascularization, as well as malignancy, tumor cell adhesion and metastasis [18]. The main regulators of Gal-3 secretion are pro-inflammatory cytokines, i.e. interferon-γ, tumor necrosis factor alpha, and interleukin-17, components of oxidative stress, free radicals, aldosterone, and transforming growth factor-beta [19].

Recent studies have shown that Gal-3 exhibits a pro-inflammatory response by recruiting and activating lymphocytes, mononuclears /macrophages and other antigen-presenting cells [20, 21]. Indeed, Gal-3 galectin-3 exerts cytokine-like regulatory actions on production of inflammasome via activation of the JAK- STAT
Galectin-3 in pulmonary hypertension

Vergaro G et al (2016) reported that Gal-3 may interact with aldosterone in promoting macrophage infiltration and vascular fibrosis. Therefore, Gal-3 contributes to cardiorenal remodeling and endothelial dysfunction induced by aldosterone. Interestingly, in animal models Gal-3 not only causes cardiac hypertrophy, but directly induces cardiac dysfunction through involvement of the transforming growth factor (TGF)-beta/Smad signaling pathway. Moreover, inhibition of Gal-3 was associated with a down-regulation in collagen I and III production, collagen processing, cleavage, cross-linking, and deposition. Taken together these data have suggested that Gal-3 could be a novel therapeutic target in cardiac fibrosis and inflammation, while clinical relevance of these findings requires more investigations.

Recent study has shown that Gal-3 appears to be localized on the osteoclast cell surface, and its suppression sufficiently inhibited osteoclast differentiation and reduced the number of mature osteoclasts. These findings elucidate the role of Gal-3 in modulation of bone mineralization / osteoporosis and link the process with inflammation. Finally, Gal-3 signaling is argued as an important mechanism of cardiac / vascular remodeling development based on inducing of hypertrophy / fibrosis and inflammation.

Gal-3 signaling in PAH

PAH is characterized by abnormal elaboration of vasoactive substance (endothelin-1, serotonin, bone morphogenetic proteins, Rho kinase, and hypoxia-inducible factor 1), endothelial cell dysfunction, vascular remodeling, and inflammation, which collectively contribute to its pathogenesis. Overall, pathogenetic transformation of the pulmonary vascular bed is argued a main cause of PAH development with and without associated various clinical phenotypes. Indeed, despite the pathogenesis of PAH is a complex and multifactorial process, inflammation could be a trigger of endothelial injury, pulmonary artery smooth muscle cell proliferation, chemoattractant over-production. There is evidence regarding the role of pulmonary arterial smooth muscle and endothelial cells in vasoconstriction, development of vaso-occlusive lesions and ventilation-perfusion mismatch. Therefore, PAH might occur due to several molecular mechanisms resulting in heterogeneous genetic defects affecting defects of the transforming growth factor beta pathway that could be regulated with Gal-3. At this pathway, Gal-3 may play a pivotal role in establishment and progression of PAH via inducing of endothelial dysfunction and hyperplasia of the underlying medial layer potentially through direct activation of (TGF)-beta/Smad3 signaling.

Elevated Gal-3 level and cardiovascular events

Elevated levels of circulating Gal-3 has found in cardiovascular (CV) disease (coronary artery disease, hypertension, heart failure, atrial fibrillation / flatter), renal and metabolic (diabetes mellitus, metabolic syndrome, obesity) disease and were strongly associated with asymptomatic atherosclerosis, premature CV events.
including myocardial infarction, acute / acutely decompensated heart failure, and sudden death [33-37]. In general population increased Gal-3 concentrations were found as predictor of CV disease and diabetes development [38, 39]. Furthermore, Gal-3 has potential relations with CV mortality and all-cause mortality beyond classical and new markers of CV risk [40, 41]. However, the predictive role of Gal-3 in PAH individuals are still not fully clear.

**Predictive value of Gal-3 in PAH**

The heterogeneity of nature evolution, clinical features, prognosis, and treatment response supports the need for identifying PAH patients at risk with various methods. Recent clinical studies have shown that clinical status, hemodynamics, several biomarkers (growth differentiation factor-15, interleukin-6, creatinine, and NT-proBNP levels) and exercise capacity may predict severity and clinical outcomes in selected cohorts of patients with PAH [11]. However, lack of universal predictive model mediate to discovery of novel biomarkers and / or utilize a multi biomarker approaches. In this context, predictive model based on Gal-3 single sample measurements could be useful for risk stratification of PAH individuals. Moreover, serial measurements of Gal-3 within treatment is argued a perspective tool for assay the positive response in long-term period affecting mortality rate in PAH. Indeed, Calvier L et al (2016) [15] reported that elevated level of Gal-3 was closely associated with severity of PAH independently etiology. Fenster BE et al. (2015) [16] presented evidence regarding sufficient relation between circulating level of Gal-3 and morphologic changes in PAH including estimate right ventricle (RV) systolic pressure and measure RV strain. Authors found that Gal-3 positively correlated with the extracellular matrix markers, i.e. tissue inhibitor of metalloproteinase-1 (TIMP-1), and hyaluronic acid. However, the evidence regarding multi maker strategy to identify patients at higher risk of PAH development and complications are very limited and requires a confirmation in the large clinical trials.

In conclusion, despite an increased interest in Gal-3 as a regulatory peptide contributed in PAH pathogenesis, there are no significant evidence regarding both single sample and serial measurements of this biomarkers aimed to improve prediction of PAH development and progression. More clinical trials are needed to explain the predictive role of Gal-3 in PAH individuals with several etiology.

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
References


http://dx.doi.org/10.1093/rheumatology/kes140


Galectin-3 in pulmonary hypertension

http://dx.doi.org/10.1007/s00380-015-0691-z

http://dx.doi.org/10.1124/jpet.114.218370

http://dx.doi.org/10.1016/j.biopha.2016.01.014

http://dx.doi.org/10.1007/s12026-012-8286-6

http://dx.doi.org/10.1016/j.ajpath.2013.01.017

http://dx.doi.org/10.1093/ecco-jcc/jjw013

http://dx.doi.org/10.4049/jimmunol.1000154


Received: March 25, 2016; Published: April 8, 2016